Immunabs
Seoul
About Immunabs
ImmunAbs specialize in antibody therapeutics in global standard development. The company develops antibody therapeutics for orphan diseases, diabetic retinopathy, and diabetes based on its experience developing antibody therapeutics that have been globally approved for sale in the United States and Europe.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $10.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2022)
- Website: immunabs.com
- Phone: +82-2-6959-3695
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immunabs-79654 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.